Free shipping on all orders over $ 500

Deforolimus

Cat. No. M1703
Deforolimus Structure
Synonym:

Ridaforolimus, AP23573, MK-8669

Size Price Availability Quantity
10mg USD 100 In stock
50mg USD 350 In stock
200mg USD 780 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

Deforolimusis (also known as Ridaforolimus, AP23573 and MK-8669) is an investigational targeted and small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN known to be important to malignancy. Deforolimusis blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.

Protocol
Cell Experiment
Cell lines HCT-116, SK-UT-1, HT-1080, SW872, MCF-7, PC-3 cell lines
Preparation method In vitro proliferation assays. Exponentially growing cell lines were plated into two 96-well plates and incubated overnight at 37°C. Twenty-four hours after plating, 1 plate (D1) was aspirated and stored at −80°C. The other plate (D4) was treated with 10-fold serial dilutions of ridaforolimus (1,000 to 0.0001 nmol/L) or vehicle (ethanol). Following 72 hours culture at 37°C, the plates were aspirated and stored at −80°C for proliferation analysis. The D1 and D4 plates were assessed simultaneously for cell growth using the CyQUANT Cell Proliferation Assay Kit (Invitrogen). Doubling time (DT) = [0.301 × (72)/log(day4/day1)]. Doublings = 72/DT. Cell growth rate (%) = doublings ridaforolimus/doublings vehicle × 100. Imax = 100 − cell growth rate (%) at the dose at which maximum inhibition is observed. Imax was used to determine the relative sensitivity of each cell line.
Concentrations 0~1000 n M
Incubation time 72 h
Animal Experiment
Animal models mice bearing PC-3, A549, HCT-116, MCF7, and PANC-1 tumors xenograft model
Formulation diluted in a vehicle of 4% ethanol, 5% Tween 80, and 5% propylene glycol
Dosages 3 and 10 mg/kg (a) daily, 5 continuous days every other week and (b) once weekly
Administration i.p.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 990.21
Formula C53H84NO14P
CAS Number 572924-54-0
Purity >99%
Solubility DMSO
Storage at -20°C
References

Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.
Keedy VL. Onco Targets Ther. 2012;5:153-60. PMID: 22942649.

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
Lush et al. Cancer Chemother Pharmacol. 2012 Aug 10. PMID: 22878520.

Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer.
Amato et al. Clin Genitourin Cancer. 2012 Jun 11. PMID: 22695254.

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
Squillace et al. Int J Oncol. 2012 Aug;41(2):425-32. PMID: 22614157.

The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
Stroh et al. Cancer Chemother Pharmacol. 2012 May;69(5):1247-53. PMID: 22290273.

Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Berk et al. Cancer Chemother Pharmacol. 2012 May;69(5):1369-77. PMID: 22231376.

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
Rivera VM, et al. Mol Cancer Ther. 2011 Jun;10(6):1059-71. PMID: 21482695.

Related mTOR Products
Zotarolimus

Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.

LY303511

LY303511 is a structural analogue of LY294002, which does not inhibit PI3K, increased homotypic GJIC.

Temsirolimus

Temsirolimus (CCI-779) is a specific mTOR inhibitor with IC50 of 1.76 μM.

WYE-125132

WYE-125132 is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR.

AZD2014

AZD2014 is a novel dual mTORC1 and mTORC2 inhibitor with potential antineoplastic activity.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Deforolimus, Ridaforolimus, AP23573, MK-8669 supplier, mTOR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.